| Overview |
| bs-2111R-BF350 |
| VP16 tag Antibody, AbBy Fluor® 350 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Tags, Others |
| Specifications |
| AbBy Fluor® 350 |
| Rabbit |
| KLH conjugated synthetic peptide derived from HSV-1 VP16 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| P04486 |
| Nucleus |
| VP16_HHV1F;UL48; Tegument protein VP16; Alpha trans-inducing protein; Alpha-TIF; ICP25; Vmw65 |
| HSV evades the immune system through interference with MHC class I antigen presentation on the cell surface, by blocking TAP or the transporter associated with antigen processing induced by the secretion of ICP-47 by HSV. In the host cell, TAP transports digested viral antigen epitope peptides from the cytosol to the endoplasmic reticulum, allowing these epitopes to be combined with MHC class I molecules and presented on the surface of the cell. Viral epitope presentation with MHC class I is a requirement for activation of cytotoxic T-lymphocytes (CTLs), the major effectors of the cell-mediated immune response against virally-infected cells. ICP-47 prevents initiation of a CTL-response against HSV, allowing the virus to survive for a protracted period in the host. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz